Aurinia Pharmaceuticals, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CA05156V1022
USD
14.81
0.01 (0.07%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
ANI Pharmaceuticals, Inc.
Aurinia Pharmaceuticals, Inc.
Vir Biotechnology, Inc.
Rhythm Pharmaceuticals, Inc.
Twist Bioscience Corp.
Iovance Biotherapeutics, Inc.
Xencor, Inc.
Merus NV
Maravai Lifesciences Holdings, Inc.
Summit Therapeutics, Inc.
Spyre Therapeutics, Inc.

Why is Aurinia Pharmaceuticals, Inc. ?

1
With a growth in Net Profit of 568.11%, the company declared Outstanding results in Sep 25
  • The company has declared positive results for the last 5 consecutive quarters
  • OPERATING CASH FLOW(Y) Highest at USD 120.64 MM
  • ROCE(HY) Highest at 20.65%
  • INTEREST COVERAGE RATIO(Q) Highest at 3,233.76
2
With ROE of 23.13%, it has a fair valuation with a 4.65 Price to Book Value
  • Over the past year, while the stock has generated a return of 81.15%, its profits have risen by 279.8% ; the PEG ratio of the company is 0.1
3
High Institutional Holdings at 61.8%
  • These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
  • Their stake has increased by 16.63% over the previous quarter.
4
Market Beating Performance
  • The stock has generated a return of 81.15% in the last 1 year, much higher than market (S&P 500) returns of 20.78%
stock-recommendationReal-Time Research Report

Verdict Report

How much should you buy?

  1. Overall Portfolio exposure to Aurinia Pharmaceuticals, Inc. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Aurinia Pharmaceuticals, Inc. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Aurinia Pharmaceuticals, Inc.
78.65%
3.89
44.73%
S&P 500
21.6%
1.08
19.33%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
205.63%
EBIT Growth (5y)
23.61%
EBIT to Interest (avg)
-74.91
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.85
Sales to Capital Employed (avg)
0.55
Tax Ratio
4.69%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
45.17%
ROCE (avg)
19.90%
ROE (avg)
3.27%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
20
Industry P/E
Price to Book Value
4.65
EV to EBIT
15.23
EV to EBITDA
12.33
EV to Capital Employed
33.72
EV to Sales
4.85
PEG Ratio
0.07
Dividend Yield
NA
ROCE (Latest)
221.36%
ROE (Latest)
23.13%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

24What is working for the Company
OPERATING CASH FLOW(Y)

Highest at USD 120.64 MM

ROCE(HY)

Highest at 20.65%

INTEREST COVERAGE RATIO(Q)

Highest at 3,233.76

DEBT-EQUITY RATIO (HY)

Lowest at -74.8 %

NET SALES(Q)

Highest at USD 73.47 MM

OPERATING PROFIT(Q)

Highest at USD 35.54 MM

PRE-TAX PROFIT(Q)

Highest at USD 31.96 MM

NET PROFIT(Q)

Highest at USD 31.55 MM

EPS(Q)

Highest at USD 0.23

0What is not working for the Company
Icon
NO KEY NEGATIVE TRIGGERS

Here's what is working for Aurinia Pharmaceuticals, Inc.

Operating Cash Flow
Highest at USD 120.64 MM and Grown
In each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Interest Coverage Ratio
Highest at 3,233.76
in the last five periods
MOJO Watch
The company's ability to manage interest payments is improving

Operating Profit to Interest

Net Sales
Highest at USD 73.47 MM
in the last five periods
MOJO Watch
Near term sales trend is positive

Net Sales (USD MM)

Operating Profit
Highest at USD 35.54 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (USD MM)

Pre-Tax Profit
Highest at USD 31.96 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Pre-Tax Profit
At USD 31.96 MM has Grown at 60.85%
over average net sales of the previous four periods of USD 19.87 MM
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit
Highest at USD 31.55 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is positive

Net Profit (USD MM)

Net Profit
At USD 31.55 MM has Grown at 62.7%
over average net sales of the previous four periods of USD 19.39 MM
MOJO Watch
Near term Net Profit trend is positive

Net Profit (USD MM)

EPS
Highest at USD 0.23
in the last five periods
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Debt-Equity Ratio
Lowest at -74.8 %
in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio